Elutia Inc. Stock

ELUT

US05479K1060

Pharmaceuticals

Delayed Nasdaq 10:30:15 2026-10-16 EDT			5-day change	1st Jan Change
0.8007 ^USD	+1.51%		-2.72%	+15.59%

10-01	Elutia Reports $8 Million Payment from Boston Scientific	MT
08-17	Cellution Biologics Llc completed the acquisition of SimpliDerm human acellular dermal matrix business of Elutia Inc. for $11 million.	CI

Last Transcript: Elutia Inc.

Elutia Inc., Q2 2026 Earnings Call, Aug 13, 2026

08-13

More transcripts

Analysts' recommendations: Elutia Inc.

25-08-18	Cantor Fitzgerald Adjusts Elutia Price Target to $5 From $7, Maintains Overweight Rating	MT
24-06-21	Lake Street Adjusts Elutia Price Target to $10 From $5, Maintains Buy Rating	MT
24-06-20	Cantor Fitzgerald Adjusts Price Target on Elutia to $11 From $5, Maintains Overweight Rating	MT
23-11-14	Cantor Fitzgerald Cuts Elutia's Price Target to $6 From $8, Keeps Overweight Rating	MT
23-09-28	Lake Street Initiates Elutia at Buy Rating With $3 Price Target	MT

More recommendations

Managers and Directors: Elutia Inc.

Manager	Title	Age	Since
Michelle Williams COO	Chief Operating Officer	52	-
Charles Mills CEO	Chief Executive Officer	54	2022-06-20
Matthew Ferguson DFI	Director of Finance/CFO	58	2020-09-27

Director	Title	Age	Since
Kevin Rakin CHM	Chairman	65	2015-10-31
Charles Mills BRD	Director/Board Member	54	2015-10-31
Brigid Makes BRD	Director/Board Member	70	2020-08-31

More insiders

Elutia Inc. is a commercial-stage company developing proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. Its cardiovascular biomatrix portfolio spans pericardial closure, intracardiac tissue repair, and vascular reconstruction. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. Its cardiovascular products are specifically designed to provide immediate structural support while promoting tissue regeneration, cellular infiltration, and natural integration over time. It is focused on developing NXT-41x, an antibiotic-eluting biomatrix designed to address post-operative infection. The NXT-41x product is designed to provide soft-tissue reinforcement while locally delivering antibiotics locally to inhibit bacterial colonization at the surgical site.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-10-16	US$0.8007	+1.51%	9,870
26-10-15	US$0.7888	+7.32%	123,877
26-10-14	US$0.7350	-4.94%	293,262
26-10-13	US$0.7732	-1.75%	36,584
26-10-12	US$0.7870	-4.39%	69,836

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.7888USD

Average target price

5.000USD

Spread / Average Target

+533.87%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Elutia Inc.

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Elutia Inc.

Company calendar

Market Cap	34.94M 31.18M 28.98M 26.36M 49.6M 3.31B 50.49M 348M 136M 1.73B 131M 128M 5.52B	P/E 2026 *	-1.25x	P/E 2027 *	-1.46x
Enterprise Value	34.94M 31.18M 28.98M 26.36M 49.6M 3.31B 50.49M 348M 136M 1.73B 131M 128M 5.52B	EV / Sales 2026 *	4.66x	EV / Sales 2027 *	8.12x
Free-Float	85.18%	Yield 2026 *	-	Yield 2027 *	-

10-01	Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029	AQ
09-10	Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th	AQ
09-02	Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference	AQ
08-19	Cellution Biologics Completes Acquisition of SimpliDerm(R) from Elutia Inc.	AQ
08-18	Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.	AQ

1 day	+1.51%
1 week	-2.72%
Current month	+1.35%
1 month	-1.15%
3 months	-15.72%
6 months	-31.56%
Current year	+15.59%

1 week	0.71	0.8
1 month	0.67	0.9
Current year	0.6	1.38
1 year	0.5	1.38
3 years	0.5	5.24
5 years	0.5	9.01
10 years	0.5	18.2

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/10/26	Charles Mills	Exercice	Founder	63,884	0.1445%
9/10/26	Michelle Williams	Exercice	Founder	29,269	0.0662%
9/10/26	Matthew Ferguson	Exercice	Chief Financial Officer	29,486	0.0667%

Elutia Inc. Stock

Stocks

ELUT

US05479K1060

Pharmaceuticals

Valuation: Elutia Inc.

Chart: Elutia Inc.

Latest news: Elutia Inc.

Last Transcript: Elutia Inc.

Analysts' recommendations: Elutia Inc.

Press Releases: Elutia Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Elutia Inc.

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELUTIA INC.	+1.51%	-2.72%	-11.04%	-44.40%	34.94M
ELI LILLY AND COMPANY	+1.02%	+7.66%	+54.95%	+105.89%	1,116B
JOHNSON & JOHNSON	+1.49%	-1.88%	+33.52%	+62.84%	610B
ABBVIE INC.	+0.51%	+3.44%	+26.05%	+94.24%	501B
MERCK & CO., INC.	+1.25%	+0.94%	+75.13%	+41.12%	358B
ROCHE HOLDING AG	-0.53%	+5.56%	+32.39%	+49.79%	366B
NOVARTIS AG	-0.99%	+4.65%	+19.46%	+42.94%	288B
ASTRAZENECA PLC	-2.09%	+3.88%	-0.72%	+13.60%	261B
AMGEN INC.	+0.63%	+5.47%	+47.92%	+52.52%	235B
GILEAD SCIENCES, INC.	-0.72%	+3.54%	+32.81%	+97.63%	195B
Average	+0.21%	+4.27%	+31.05%	+51.62%	392.98B
Weighted average by Cap.	+0.45%	+4.93%	+39.86%	+72.25%

	2026 *	2027 *
Net sales	7.5M 6.69M 6.22M 5.66M 10.65M 710M 10.84M 74.74M 29.24M 371M 28.15M 27.55M 1.19B	4.3M 3.84M 3.57M 3.24M 6.1M 407M 6.21M 42.85M 16.77M 212M 16.14M 15.79M 680M
Net income	-27.3M -24.37M -22.65M -20.6M -38.76M -2.59B -39.46M -272M -106M -1.35B -102M -100M -4.32B	-23.6M -21.07M -19.58M -17.81M -33.51M -2.24B -34.11M -235M -92.02M -1.17B -88.56M -86.69M -3.73B
Net Debt	-	-